The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE).

Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of hereditary angioedema (HAE) attacks in patients 12 years and older.

The antibody-based drug Andembry is the first to target factor XIIa, a protein responsible for swelling in people with this rare genetic disorder.

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the inflammatory cascade that drives attacks.

Ari Aster's Hereditary NON SPOILER REVIEW - Is Hereditary the scariest movie of 2018? We discuss the creepiness of this movie starring Toni Collette, Alex Wolff, Milly Shapiro, Ann Dowd, and ...

Hereditary cancer testing offers genetic insights that can guide care for cancers linked to inherited variants such as breast, colorectal, ovarian, pancreatic and prostate cancers.

The FDA has accepted the New Drug Application for berotralstat as prophylactic therapy for pediatric patients aged 2 to 11 years with hereditary angioedema.

Hyperekplexia (HK) is an infrequent neurological disorder characterized by excessive startle responses noticed shortly after birth. 1, 2 It is a form of startle syndrome and can be divided into three ...

SAN DIEGO — Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer attacks and improved disease control, according to a ...

Hereditary angioedema (HAE) is a rare condition that causes fluid to build up throughout your body, triggering sudden and repeated serious swelling. This is the most common type and happens ...

Hereditary cancers occur as a result of inherited genetic dispositions passed from parent to child. About 10% of cancer diagnoses qualify as hereditary cancer. Luckily, we have many testing strategies ...